Experimental HIV Drugs
Experimental HIV Drugs
HIV Drug Development News from IAS 2011 [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 July 2011 00:00
- Written by Gregory Fowler
Cal Cohen from the Community Research Institute of New England summarizes reports about experimental antiretroviral agents -- and new strategies for using existing drugs -- presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Rome. 
IAS 2011: Once-daily Elvitegravir Matches Twice-daily Raltegravir
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 July 2011 00:00
- Written by Liz Highleyman
The experimental HIV integrase inhibitor elvitegravir works as well as raltegravir (Isentress) for treatment-experienced people with extensive drug resistance, and was well-tolerated overall, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome. 
Tobira Starts Phase 2b Cenicriviroc Trial
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 28 June 2011 06:41
- Written by Tobira
Tobira Therapeutics recently opened a middle-phase trial of its dual CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Gilead and Tibotec To Develop New Combo Pill
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 05 July 2011 12:08
- Written by Gilead Sciences
Gilead Sciences and Tibotec Pharmaceuticals announced a collaboration to develop a fixed-dose combination pill containing the protease inhibitor darunavir (Prezista) plus the novel boosting agent cobicistat.
TBR-652 Inhibits HIV, May Dampen Inflammation
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 31 May 2011 03:31
- Written by Liz Highleyman
TBR-652, a drug that blocks both CCR5 and CCR2 cell receptors, showed potent antiviral activity against HIV, but did not change most inflammation biomarkers.
Web Design and Development by